Compare THM & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | ANNX |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | Canada | United States |
| Employees | N/A | 93 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.5M | 812.7M |
| IPO Year | 2002 | 2020 |
| Metric | THM | ANNX |
|---|---|---|
| Price | $2.47 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16,320.74 |
| P/E Ratio | $244.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $1.85 |
| 52 Week High | $3.65 | $7.18 |
| Indicator | THM | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 44.32 |
| Support Level | $2.21 | $5.28 |
| Resistance Level | $2.84 | $5.61 |
| Average True Range (ATR) | 0.17 | 0.29 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 34.37 | 41.18 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.